We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CONMED Q2 Earnings and Revenues Beat Estimates, Gross Margin Expands
Read MoreHide Full Article
Key Takeaways
CONMED's Q2 adjusted EPS rose 20% to $1.38, while revenues edged up 0.3% to $343.5 million.
International organic sales grew 9.9%, led by strength in AirSeal, Buffalo Filter and BioBrace.
CONMED raised 2026 adjusted EPS guidance to $4.48-$4.60 as gross margin expanded 300 basis points.
CONMED Corporation (CNMD - Free Report) posted adjusted earnings per share (EPS) of $1.38 for the second quarter of 2026, up 20% year over year. The figure beat the Zacks Consensus Estimate by 25.5%.
The adjustments include costs related to legal matters and contingent consideration fair value adjustments, among others.
GAAP EPS for the quarter was 77 cents, up 11.6% from the year-ago period’s EPS of 69 cents.
CNMD's Organic Sales Gain Momentum
CNMD’s second-quarter revenues of $343.5 million increased 0.3% year over year and beat the consensus estimate by 1.9%. International strength and growth across the company’s key AirSeal, Buffalo Filter and BioBrace platforms supported the quarter.
Shares of CNMD gained 6.3 in today’s pre-market trading. In the year-to-date period, shares of the company gained 6.4% compared with the industry’s 3.3% growth. The S&P 500 increased 8.1% in the same time frame.
At constant currency, total revenues declined 0.5% year over year. However, excluding sales tied to CONMED’s strategic exit from certain gastroenterology product offerings, organic constant-currency revenues increased 6%.
Domestic sales totaled $175.4 million, down 8% on a reported basis. Excluding the GI exits, domestic organic revenues rose 2.5%. International sales reached $168.1 million, up 10.8% on a reported basis and 8.9% at constant currency. International organic constant-currency growth was 9.9%.
Image Source: Zacks Investment Research
CONMED's Orthopedic Revenues Increase
Orthopedic Surgery revenues totaled $152.3 million, up 8.2% year over year on a reported basis and 6.8% at constant currency. International orthopedic revenues advanced 10.8% at constant exchange rates, reflecting broad-based growth across major regions.
Domestic orthopedic sales were nearly flat and fell short of management’s expectations. Nonetheless, the company continued to strengthen its U.S. commercial organization. BioBrace was a major contributor, supported by adoption across orthopedic and foot-and-ankle procedures, particularly rotator cuff repair.
CNMD's General Surgery Business Improves
General Surgery revenues were $191.2 million, down 5.2% on a reported basis and 5.6% at constant currency. The decline reflected the impact of the GI portfolio exits. On an organic constant-currency basis, General Surgery sales increased 5.3%.
AirSeal and Buffalo Filter led the underlying growth. AirSeal sales increased across capital and single-use products and improved sequentially, but growth remained below management’s expectations. CONMED expects AirSeal trends to improve during the second half of 2026, but at a slower rate than previously assumed.
Direct smoke evacuation sales exceeded the company’s long-term expectation of high-single-digit to low-double-digit growth. This more than offset a modest decline in original equipment manufacturer smoke evacuation sales.
The company continues to prioritize its direct Buffalo Filter portfolio, which carries a stronger margin profile and brings CONMED closer to customers. Management also highlighted early commercial traction in Europe, Canada and Australia, along with expanding U.S. legislation requiring surgical smoke evacuation systems.
CONMED’s Margin Analysis
In the quarter under review, CNMD’s adjusted gross profit increased 5.6% year over year to $204.4 million. The adjusted gross margin expanded 300 basis points (bps) to 59.5%. The improvement included an $8.5 million benefit from tariff refunds, which contributed nearly 250 bps to the year-over-year expansion.
In the quarter under review, CNMD’s reported gross profit increased 4.9% year over year to $197.5 million. The gross margin expanded 250 bps to 57.5%.
Selling & administrative expenses increased 7% year over year to $145.6 million. Research and development expenses rose 9.6% year over year to $15.5 million. Total operating expenses of $161.1 million increased 7.3% on a year-over-year basis.
Total operating profit totaled $36.4 million, reflecting a 4.6% decrease from the year-ago quarter. The operating margin contracted 50 bps to 10.6%.
CONMED Corporation Price, Consensus and EPS Surprise
The company exited the second quarter with cash and cash equivalents of $37.3 million compared with $35 million a year ago.
Cumulative net cash provided by operating activities at the end of second-quarter 2026 was $50.6 million compared with $70.7 million a year ago.
CONMED’s Guidance
CNMD has updated its outlook for 2026.
For 2026, total reported revenues are expected to be in the range of $1,358 million-$1,373 million compared with the previous guidance of $1,350 million-$1,375 million. This represents a reported revenue decline of 1.2-0.1% year over year.
Organic constant-currency revenue growth is expected to be 5-6% compared with the prior projection of 5-6.5%. The revised outlook reflects second-quarter performance and a more measured pace of sequential growth improvement in the second half of 2026.
The company now expects adjusted EPS for 2026 in the range of $4.48-$4.60, up from its previous guidance of $4.30-$4.45. The raised outlook reflects better-than-expected second-quarter results, a lower projected headwind from the GI product exits and a higher contribution from share repurchases. These benefits are expected to be partly offset by higher interest expenses and an increased tax-rate assumption.
CONMED expects third-quarter revenues to be in the range of $334 million-$339 million. Organic constant-currency growth is projected to be between 6.4% and 7.6%, excluding anticipated GI revenues of $3 million-$3.6 million and an approximately 10-basis-point foreign currency impact. Adjusted EPS is expected to be between 98 cents and $1.03.
Our Take on CNMD
CONMED exited the second quarter of 2026 with better-than-expected earnings and revenues. Organic constant-currency sales growth of 6% reflected gains across both Orthopedic Surgery and General Surgery, supported by continued momentum in AirSeal, Buffalo Filter and BioBrace. The completion of the GI portfolio exit should allow the company to sharpen its focus on these core growth platforms.
AirSeal continues to benefit from opportunities in robotic and laparoscopic procedures, although second-quarter growth was below management’s expectations. Buffalo Filter remains well positioned to gain from expanding smoke-evacuation legislation and international adoption, while BioBrace continues to see traction in rotator cuff repair and other orthopedic procedures. Improved supply-chain execution, including lower backorders and stronger service levels, should also support more consistent operating performance.
However, challenges remain. The GI exit continues to weigh on reported revenues, while AirSeal’s growth outlook for the second half is lower than previously assumed. Domestic orthopedic sales were nearly flat, and modest weakness in the OEM smoke-evacuation business also pressured General Surgery. Moreover, higher interest expenses following the debt refinancing may limit earnings growth. Despite these headwinds, CONMED raised its adjusted earnings outlook for 2026 and continues to expect organic constant-currency growth of 5-6%.
CONMED’s Zacks Rank & Stocks to Consider
CNMD currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are McKesson (MCK - Free Report) , Phibro Animal Health (PAHC - Free Report) andCardinal Health (CAH - Free Report) .
McKesson carries a Zacks Rank #2 (Buy) at present and has an estimated long-term growth rate of 13.7%. MCK’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.09%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
McKesson shares have gained 8.8% against the industry’s 12.7% decline in the year-to-date period.
Phibro Animal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 21.5%. PAHC’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 16.25%.
Phibro Animal Health stock has climbed 44.2% against the industry’s 17.1% decline in the year-to-date period.
Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%.
Cardinal Health’s shares have lost 2.6% compared with the industry’s 3.1% decline in the year-to-date period.
View the Zacks #1 Rank List
Image: Bigstock
CONMED Q2 Earnings and Revenues Beat Estimates, Gross Margin Expands
Key Takeaways
CONMED Corporation (CNMD - Free Report) posted adjusted earnings per share (EPS) of $1.38 for the second quarter of 2026, up 20% year over year. The figure beat the Zacks Consensus Estimate by 25.5%.
The adjustments include costs related to legal matters and contingent consideration fair value adjustments, among others.
GAAP EPS for the quarter was 77 cents, up 11.6% from the year-ago period’s EPS of 69 cents.
CNMD's Organic Sales Gain Momentum
CNMD’s second-quarter revenues of $343.5 million increased 0.3% year over year and beat the consensus estimate by 1.9%. International strength and growth across the company’s key AirSeal, Buffalo Filter and BioBrace platforms supported the quarter.
Shares of CNMD gained 6.3 in today’s pre-market trading. In the year-to-date period, shares of the company gained 6.4% compared with the industry’s 3.3% growth. The S&P 500 increased 8.1% in the same time frame.
At constant currency, total revenues declined 0.5% year over year. However, excluding sales tied to CONMED’s strategic exit from certain gastroenterology product offerings, organic constant-currency revenues increased 6%.
Domestic sales totaled $175.4 million, down 8% on a reported basis. Excluding the GI exits, domestic organic revenues rose 2.5%. International sales reached $168.1 million, up 10.8% on a reported basis and 8.9% at constant currency. International organic constant-currency growth was 9.9%.
Image Source: Zacks Investment Research
CONMED's Orthopedic Revenues Increase
Orthopedic Surgery revenues totaled $152.3 million, up 8.2% year over year on a reported basis and 6.8% at constant currency. International orthopedic revenues advanced 10.8% at constant exchange rates, reflecting broad-based growth across major regions.
Domestic orthopedic sales were nearly flat and fell short of management’s expectations. Nonetheless, the company continued to strengthen its U.S. commercial organization. BioBrace was a major contributor, supported by adoption across orthopedic and foot-and-ankle procedures, particularly rotator cuff repair.
CNMD's General Surgery Business Improves
General Surgery revenues were $191.2 million, down 5.2% on a reported basis and 5.6% at constant currency. The decline reflected the impact of the GI portfolio exits. On an organic constant-currency basis, General Surgery sales increased 5.3%.
AirSeal and Buffalo Filter led the underlying growth. AirSeal sales increased across capital and single-use products and improved sequentially, but growth remained below management’s expectations. CONMED expects AirSeal trends to improve during the second half of 2026, but at a slower rate than previously assumed.
Direct smoke evacuation sales exceeded the company’s long-term expectation of high-single-digit to low-double-digit growth. This more than offset a modest decline in original equipment manufacturer smoke evacuation sales.
The company continues to prioritize its direct Buffalo Filter portfolio, which carries a stronger margin profile and brings CONMED closer to customers. Management also highlighted early commercial traction in Europe, Canada and Australia, along with expanding U.S. legislation requiring surgical smoke evacuation systems.
CONMED’s Margin Analysis
In the quarter under review, CNMD’s adjusted gross profit increased 5.6% year over year to $204.4 million. The adjusted gross margin expanded 300 basis points (bps) to 59.5%. The improvement included an $8.5 million benefit from tariff refunds, which contributed nearly 250 bps to the year-over-year expansion.
In the quarter under review, CNMD’s reported gross profit increased 4.9% year over year to $197.5 million. The gross margin expanded 250 bps to 57.5%.
Selling & administrative expenses increased 7% year over year to $145.6 million. Research and development expenses rose 9.6% year over year to $15.5 million. Total operating expenses of $161.1 million increased 7.3% on a year-over-year basis.
Total operating profit totaled $36.4 million, reflecting a 4.6% decrease from the year-ago quarter. The operating margin contracted 50 bps to 10.6%.
CONMED Corporation Price, Consensus and EPS Surprise
CONMED Corporation price-consensus-eps-surprise-chart | CONMED Corporation Quote
CNMD’s Financial Position
The company exited the second quarter with cash and cash equivalents of $37.3 million compared with $35 million a year ago.
Cumulative net cash provided by operating activities at the end of second-quarter 2026 was $50.6 million compared with $70.7 million a year ago.
CONMED’s Guidance
CNMD has updated its outlook for 2026.
For 2026, total reported revenues are expected to be in the range of $1,358 million-$1,373 million compared with the previous guidance of $1,350 million-$1,375 million. This represents a reported revenue decline of 1.2-0.1% year over year.
Organic constant-currency revenue growth is expected to be 5-6% compared with the prior projection of 5-6.5%. The revised outlook reflects second-quarter performance and a more measured pace of sequential growth improvement in the second half of 2026.
The company now expects adjusted EPS for 2026 in the range of $4.48-$4.60, up from its previous guidance of $4.30-$4.45. The raised outlook reflects better-than-expected second-quarter results, a lower projected headwind from the GI product exits and a higher contribution from share repurchases. These benefits are expected to be partly offset by higher interest expenses and an increased tax-rate assumption.
CONMED expects third-quarter revenues to be in the range of $334 million-$339 million. Organic constant-currency growth is projected to be between 6.4% and 7.6%, excluding anticipated GI revenues of $3 million-$3.6 million and an approximately 10-basis-point foreign currency impact. Adjusted EPS is expected to be between 98 cents and $1.03.
Our Take on CNMD
CONMED exited the second quarter of 2026 with better-than-expected earnings and revenues. Organic constant-currency sales growth of 6% reflected gains across both Orthopedic Surgery and General Surgery, supported by continued momentum in AirSeal, Buffalo Filter and BioBrace. The completion of the GI portfolio exit should allow the company to sharpen its focus on these core growth platforms.
AirSeal continues to benefit from opportunities in robotic and laparoscopic procedures, although second-quarter growth was below management’s expectations. Buffalo Filter remains well positioned to gain from expanding smoke-evacuation legislation and international adoption, while BioBrace continues to see traction in rotator cuff repair and other orthopedic procedures. Improved supply-chain execution, including lower backorders and stronger service levels, should also support more consistent operating performance.
However, challenges remain. The GI exit continues to weigh on reported revenues, while AirSeal’s growth outlook for the second half is lower than previously assumed. Domestic orthopedic sales were nearly flat, and modest weakness in the OEM smoke-evacuation business also pressured General Surgery. Moreover, higher interest expenses following the debt refinancing may limit earnings growth. Despite these headwinds, CONMED raised its adjusted earnings outlook for 2026 and continues to expect organic constant-currency growth of 5-6%.
CONMED’s Zacks Rank & Stocks to Consider
CNMD currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are McKesson (MCK - Free Report) , Phibro Animal Health (PAHC - Free Report) andCardinal Health (CAH - Free Report) .
McKesson carries a Zacks Rank #2 (Buy) at present and has an estimated long-term growth rate of 13.7%. MCK’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.09%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
McKesson shares have gained 8.8% against the industry’s 12.7% decline in the year-to-date period.
Phibro Animal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 21.5%. PAHC’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 16.25%.
Phibro Animal Health stock has climbed 44.2% against the industry’s 17.1% decline in the year-to-date period.
Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%.
Cardinal Health’s shares have lost 2.6% compared with the industry’s 3.1% decline in the year-to-date period.